Latest News:

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial

POSTED: December 7, 2023

MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decades
MC2-25 CKD uses a ...
READ FULL ARTICLE >

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

POSTED: November 23, 2023

MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skin
MC2-25 ...
READ FULL ARTICLE >

MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV

POSTED: October 11, 2023

MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in randomized, double-blinded, placebo-controlled trial in 15 patients:
- Primary ...
  READ FULL ARTICLE >

MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications

POSTED: September 25, 2023

Option to exclusively license the rights to develop, manufacture and commercialize “RGRN-305” for all human indications, incl. oral treatment of Hidradenitis Suppurativa (“HS”)
RGRN-305 is a new chemical entity having a ...
READ FULL ARTICLE >

MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora® Cream in Greater China

POSTED: August 31, 2023

Copenhagen, Denmark and Hangzhou, China, August 31^st, 2023 – MC2 Therapeutics, Ltd (“MC2”), a wholly owned subsidiary of MC2 Therapeutics A/S and Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly ...

READ FULL ARTICLE >

MC2 Therapeutics to present at BIO CEO & Investor Conference 2023

POSTED: January 31, 2023

Copenhagen, January 31^st, 2023 – MC2 Therapeutics A/S, a commercial stage pharmaceutical company, engaged in research in skin biology and development of novel treatment paradigms for autoimmune and chronic inflammatory ...